{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:26:02Z","timestamp":1788395162390,"version":"build-2803163510"},"reference-count":32,"publisher":"Informa UK Limited","issue":"1-2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/14712598.2024.2310148","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:01:37Z","timestamp":1707717697000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Epcoritamab in B-cell malignancies: current status and prospects"],"prefix":"10.1080","volume":"24","author":[{"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department Haematology, Azienda Ospedaliera-Universitaria \u201cRenato Dulbecco\u201d, Catanzaro, Italy"},{"name":"Universit\u00e0 Magna Graecia, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6109","authenticated-orcid":false,"given":"David","family":"Allsup","sequence":"additional","affiliation":[{"name":"Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK"},{"name":"Centre of Biomedicine, Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,11]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8006"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/20363613231193566"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00430-6"},{"key":"e_1_3_3_14_1","unstructured":"Genmab announces European Commission approval of tepkinly (epcoritamab) for adults with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). News Release. Genmab A\/S. Sep 25 2023 Accessed oct 23 2023."},{"key":"e_1_3_3_15_1","unstructured":"Genmab and AbbVie announce positive topline results from phase 1\/2 EPCORE\u2122 NHL-1 trial evaluating epcoritamab (DuoBody\u00ae CD3xCD20) in patients with relapsed\/refractory follicular lymphoma (FL). News Release. Genmab. Jun 28 2023 Accessed Jun 28 2023. Available from: https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-and-abbvie-announce-positive-topline-results-phase-12"},{"key":"e_1_3_3_16_1","volume-title":"Presented at: 2023 International Workshop on CLL","author":"Kater AP","unstructured":"Kater AP, Eradat H, Niemann CU, et al. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b\/2 EPCORE CLL-1 trial expansion cohort. Presented at: 2023 International Workshop on CLL; 2023 Oct 6\u20139; Boston. Abstract 1546171."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)00355-5"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159544"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847720.26592.b6"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3166_OT28"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737"},{"key":"e_1_3_3_24_1","volume-title":"Presented at: 65th American Society of Hematology Annual Meeting and Exposition","author":"Linton K","unstructured":"Linton K, Jurczak W, Lugtenburg P, et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the EPCORE NHL-1 follicular lymphoma dose-expansion cohort. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; Dec 9-12, 2023; San Diego, CA: Abstract 1655"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967800.55471.36"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1946"},{"issue":"3","key":"e_1_3_3_28_1","first-page":"134","article-title":"CAR T-cell therapy for CLL: a new addition to our treatment toolbox?","volume":"21","author":"Iovino L","year":"2023","unstructured":"Iovino L, Shadman M. CAR T-cell therapy for CLL: a new addition to our treatment toolbox? Clin Adv Hematol Oncol. 2023;21(3):134\u2013141.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-15829"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009517"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971492.92995.27"},{"issue":"1","key":"e_1_3_3_32_1","first-page":"370","article-title":"Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas","volume":"2023","author":"Major A","year":"2023","unstructured":"Major A, Kamdar M. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. Hematology Am Soc Hematol Educ Program 2023. 2023 Dec 8;2023(1):370\u2013381.","journal-title":"Hematology Am Soc Hematol Educ Program 2023"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000508"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2285978"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2310148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T12:55:09Z","timestamp":1727268909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2310148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/14712598.2024.2310148"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2310148","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}